Literature DB >> 491733

Plasma vasopressin levels and urinary flow during cardiopulmonary bypass in patients with valvular heart disease: effect of pulsatile flow.

D M Philbin, F H Levine, C W Emerson, C H Coggins, M J Buckley, W G Austen.   

Abstract

The effect of pulsatile flow on plasma vasopressin levels during cardiopulmonary bypass (CPB) was studied in 20 patients undergoing open valve replacement. Routine bypass was used in 10 patients and the AVCO pulsatile bypass pump was utilized in the other 10. In Group I (nonpulsatile) during CPB, the vasopressin level was markedly elevated (3.1 +/- 2 to 80 +/- 22 pg/ml) as was urine flow (0.6 +/- 0.2 to 5.9 +/- 2 ml/min) and urine Na+ concentration (69 +/- 19 to 116 +/- 7 mEq/L). In Group II (pulsatile) during CPB, the vasopressin level (3.8 +/- 3 to 54 +/- 14 pg/ml), urine flow (0.6 +/- 0.1 to 16.2 +/- 4.8 ml/min), and urine Na+ concentrations (61 +/- 13 to 97 +/- 10 mEq/L) were also elevated. The rise in vasopressin and urine Na+ was less in the pulsatile group (p less than 0.05) whereas the urine flow was higher (p less than 0.05). To maintain comparable blood pressure, the pulsatile flow group required significantly higher flows (4.5 +/- 0.2 compared to 3.8 +/- 0.2; p less than 0.05). These data suggest that CPB produces a marked vasopressin stress response which is beyond the physiological range for an antidiuretic effect on the kidney. At these levels vasopressin can exert a vasopressor effect to maintain resistance and affect renal blood flow, as well as producing an Na+ diuresis. The addition of pulsatile flow creates a more physiological situation attenuating the vasopressin response and producing a decrease in systemic resistance and a less pronounced Na+ diuresis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 491733

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Perioperative urinary excretion of aquaporin-2 dependent upon vasopressin in cardiac surgery.

Authors:  Masahiro Fujii; Ryosuke Amitani; Ryuzo Bessho
Journal:  Heart Vessels       Date:  2019-11-07       Impact factor: 2.037

Review 2.  Effect of cardiopulmonary bypass on the pharmacokinetics of drugs.

Authors:  F O Holley; K V Ponganis; D R Stanski
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

3.  Haemodynamic and plasma vasopressin responses with high-dose fentanyl anaesthesia during aorto-coronary bypass operations.

Authors:  L A Crone; N Wilson; J Ngsee; K W Turnbull; K Leighton
Journal:  Can Anaesth Soc J       Date:  1982-11

4.  Pulsatile cardiopulmonary bypass for patients with renal insufficiency.

Authors:  G N Olinger; L D Hutchinson; L I Bonchek
Journal:  Thorax       Date:  1983-07       Impact factor: 9.139

5.  Role of renin-angiotensin system in cardiopulmonary bypass hypertension.

Authors:  G E Townsend; J E Wynands; D G Whalley; P Wong; D R Bevan
Journal:  Can Anaesth Soc J       Date:  1984-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.